Droplet Scientific Ltd has raised $2.0M in seed funding to push its point-of-care analyser toward real-time biomarker monitoring. TusPark UK and Hope Sky Capital backed the round.
The company's platform is designed to measure lactate, glucose, hormones, and therapeutic drugs in near real time, with accuracy comparable to lab equipment. The pitch: traditional blood and tissue sampling gives clinicians delayed snapshots, missing the trends that matter when deciding care.


















